A securities class action has been filed in the USDC — E.D. WI. against ESSA Pharma Inc. (EPIX) (“ESSA ” or the “Company”), on behalf of all persons or entities who purchased or otherwise acquired ESSA securities between December 12, 2023, and October 31, 2024, both dates inclusive (the “Class Period”).
ESSA is a clinical stage pharmaceutical company that focuses on the development of small molecule drugs for the treatment of prostate cancer. At all relevant times the Company’s lead product candidate was masofaniten (EPI-7386), an investigational, oral, small molecule inhibitor of the androgen receptor (“AR”), which plays a pivotal role in the development and progression of prostate cancer, especially castration-resistant prostate cancer (“CRPC”).
The Complaint alleges that, throughout the Class Period, the Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:
(1) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone;
(2) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than Defendants had led investors to believe;
(3) the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint;
(4) accordingly, Defendants had overstated masofaniten’s clinical, regulatory, and commercial prospects; and
(5) as a result, Defendants’ public statements were materially false and misleading at all relevant times, thereby harming investors.
If you purchased ESSA securities during the class period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.
About Lowey Dannenberg
Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.